Recent Updates
Recently added Catalysts
BBOT Positive Sentiment Score: 70/100

Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering Boston, Massachusetts

Key Takeaway: Helix Acquisition Corp. II has announced the pricing of its upsized initial public offering at $160 million, with 16 million Class A ordinary shares priced at $10.00 each. The shares will be listed on The Nasdaq under the ticker symbol 'HLXB' starting February 9, 2024. The company, which targets opportunities in the healthcare sector, also has provisions for underwriters to purchase additional shares to cover over-allotments. The IPO's completion is anticipated on February 13, 2024, but is subject to various conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successfully priced an upsized IPO of $160 million.
  • Shares will be listed on The Nasdaq Global Market, enhancing visibility.
  • Focus on healthcare or healthcare-related industries aligns with growth sectors.

CONCERNS & RISKS

  • The offering is contingent on a number of uncertain factors.
  • No guarantees that the anticipated use of net proceeds will be realized.

Full Press Release Details

Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million
Initial Public Offering
Boston, Massachusetts-February 9, 2024-Helix Acquisition
Corp. II (the "Company") announced today that it priced its upsized initial public offering of 16,000,000 Class A ordinary
shares at $10.00 per share. The shares will be listed on The Nasdaq Global Market and trade under the ticker symbol "HLXB"
beginning today. The Company expects the offering to be consummated on February 13, 2024.
The Company is a special purpose acquisition company formed for the
purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with
one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to
focus on opportunities in healthcare or healthcare-related industries. The Company, sponsored by Helix Holdings II LLC, an affiliate of
Cormorant Asset Management, is led by Bihua Chen as Chief Executive Officer and Chairperson, and Caleb Tripp as Chief Financial Officer.
Leerink Partners is serving as the sole bookrunning manager for the
offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 2,400,000 Class A ordinary shares at
the initial public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.
The offering is being made only by means of a prospectus. When available,
copies of the prospectus may be obtained from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston,
MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.
A registration statement relating to these securities became effective
on February 8, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there
be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains statements that constitute "forward-looking
statements," including with respect to the initial public offering and the anticipated use of the net proceeds. No assurance can
be given that the offering discussed above will be completed on the terms described, or at all, or that the net proceeds of the offering
will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the
Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for
the Company's offering filed with the Securities and Exchange Commission (the "SEC"). Copies are available on the SEC's website,
www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release,
except as required by law.
Helix Acquisition Corp. II

Frequently Asked Questions

When is Helix Acquisition Corp. II's IPO expected to close?

The IPO is expected to be completed on February 13, 2024.

How much did Helix Acquisition Corp. II raise in its IPO?

The company raised $160 million in its upsized IPO.

What ticker symbol will Helix Acquisition Corp. II use?

The company will trade under the ticker symbol 'HLXB' on Nasdaq.

What is the primary focus of Helix Acquisition Corp. II?

The company aims to focus on opportunities in healthcare-related industries.

Who is managing the IPO for Helix Acquisition Corp. II?

Leerink Partners is the sole bookrunning manager for the offering.

Last updated: Feb 9, 2024